{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:00:40Z","timestamp":1790816440332,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejca.2021.01.008","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T09:24:02Z","timestamp":1613381042000},"page":"56-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":235,"special_numbering":"C","title":["Consensus on molecular imaging and theranostics in neuroendocrine neoplasms"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5008-5351","authenticated-orcid":false,"given":"Valentina","family":"Ambrosini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Kunikowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-7383","authenticated-orcid":false,"given":"Lisa","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bouvier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cremonesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2999-1958","authenticated-orcid":false,"given":"Clarisse","family":"Dromain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9309-1604","authenticated-orcid":false,"given":"Melpomeni","family":"Fani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-0824","authenticated-orcid":false,"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"Kabasakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kaltsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Lewington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Minozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Cinquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell","family":"\u00d6berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8235-7078","authenticated-orcid":false,"given":"Wim. J.G.","family":"Oyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dermot","family":"O'Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ruszniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8405-218X","authenticated-orcid":false,"given":"Jonathan","family":"Strosberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Sundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ta\u00efeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Virgolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-7259","authenticated-orcid":false,"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1875-3962","authenticated-orcid":false,"given":"James","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2021.01.008_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2021.01.008_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.01.008_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.dld.2009.07.018","article-title":"Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours","volume":"42","author":"Zamora","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.ejca.2021.01.008_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.ejca.2021.01.008_bib5","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1677\/ERC-09-0078","article-title":"Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors","volume":"17","author":"Kwekkeboom","year":"2010","journal-title":"Endocr Relat Canc"},{"issue":"13","key":"10.1016\/j.ejca.2021.01.008_bib6","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.01.008_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2021.01.008_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.ejca.2021.01.008_bib9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000471879","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging","volume":"105","author":"Sundin","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"10","key":"10.1016\/j.ejca.2021.01.008_bib10","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European association of nuclear medicine practice guideline\/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Ta\u00efeb","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"11","key":"10.1016\/j.ejca.2021.01.008_bib11","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00259-018-4070-8","article-title":"Guidelines on nuclear medicine imaging in neuroblastoma","volume":"45","author":"Bar-Sever","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"9","key":"10.1016\/j.ejca.2021.01.008_bib12","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2","key":"10.1016\/j.ejca.2021.01.008_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000443170","article-title":"ENETS consensus guidelines update for neuroendocrine neoplasms of the Jejunum and ileum","volume":"103","author":"Niederle","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.ejca.2021.01.008_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","article-title":"EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma","volume":"47","author":"Giovanella","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"12","key":"10.1016\/j.ejca.2021.01.008_bib15","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.01.008_bib16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","article-title":"The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American neuroendocrine tumor society","volume":"46","author":"Howe","year":"2017","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.ejca.2021.01.008_bib17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000443172","article-title":"ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas","volume":"103","author":"Garcia-Carbonero","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejca.2021.01.008_bib18","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/ijc.32678","article-title":"Unmet needs in the international neuroendocrine tumor (NET) community: assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals","volume":"146","author":"Leyden","year":"2020","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2021.01.008_bib19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2967\/jnumed.109.066134","article-title":"The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy","volume":"51","author":"Srirajaskanthan","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2021.01.008_bib20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2967\/jnumed.115.165803","article-title":"68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"57","author":"Deppen","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2021.01.008_bib21","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/RLU.0000000000001877","article-title":"Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors: the impact of 99mTc-HYNICTOC SPECT\/SPECT\/CT versus 68Ga-DOTATATE PET\/CT upon clinical management","volume":"42","author":"Kunikowska","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ejca.2021.01.008_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jclinepi.2015.07.010","article-title":"A principal component analysis is conducted for a case series quality appraisal checklist","volume":"69","author":"Guo","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2021.01.008_bib23","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.ejca.2021.01.008_bib24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2021.01.008_bib25","unstructured":"Higgins, J G S. Cochrane handbook for systematic reviews of interventions. [Accessed 17 January 2020]. https:\/\/handbook-5-1.cochrane.org\/."},{"key":"10.1016\/j.ejca.2021.01.008_bib26","unstructured":"Delphi method|RAND. [Accessed 22 November 2017]. https:\/\/www.rand.org\/topics\/delphi-method.html."},{"issue":"1","key":"10.1016\/j.ejca.2021.01.008_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"issue":"5","key":"10.1016\/j.ejca.2021.01.008_bib28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrurol.2017.26","article-title":"Expert consensus document: semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure","volume":"14","author":"Bruinsma","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"6","key":"10.1016\/j.ejca.2021.01.008_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100227","article-title":"Using a Delphi technique to seek consensus regarding definitions, descriptions and classification of terms related to implicit and explicit forms of motor learning","volume":"9","author":"Kleynen","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2021.01.008_bib30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2288-6-2","article-title":"BMC medical research methodology protocol of the COSMIN study: COnsensus-based standards for the selection of health measurement INstruments","volume":"6","author":"Mokkink","year":"2006","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"10.1016\/j.ejca.2021.01.008_bib31","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/S1470-2045(11)70215-7","article-title":"Consensus-based standards for best supportive care in clinical trials in advanced cancer","volume":"13","author":"Zafar","year":"2012","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.01.008_bib32","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nurs"},{"issue":"5","key":"10.1016\/j.ejca.2021.01.008_bib33","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2967\/jnumed.116.185587","article-title":"The impact of somatostatin receptor-directed PET\/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis","volume":"58","author":"Barrio","year":"2017","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.ejca.2021.01.008_bib34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1754-9485.2012.02344.x","article-title":"18F-FDG-PET and 18F-FDG-PET\/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis","volume":"56","author":"Cheng","year":"2012","journal-title":"J Med Imag Radiat Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2021.01.008_bib35","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s00259-013-2482-z","article-title":"Somatostatin receptor PET\/CT in neuroendocrine tumours: update on systematic review and meta-analysis","volume":"40","author":"Geijer","year":"2013","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"9","key":"10.1016\/j.ejca.2021.01.008_bib36","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.2967\/jnumed.117.191197","article-title":"68Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and metaanalysis","volume":"58","author":"Graham","year":"2017","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.ejca.2021.01.008_bib37","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/RLU.0000000000002276","article-title":"68Ga PET imaging in patients with neuroendocrine tumors: a systematic review and meta-analysis","volume":"43","author":"Singh","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.ejca.2021.01.008_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.115.166017","article-title":"The impact of 68Ga-DOTATATE PET\/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom","volume":"57","author":"Skoura","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2021.01.008_bib39","article-title":"PET imaging in recurrent medullary thyroid carcinoma","volume":"2012","author":"Treglia","year":"2012","journal-title":"Int J Mol Imag"},{"issue":"7","key":"10.1016\/j.ejca.2021.01.008_bib40","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00259-012-2087-y","article-title":"Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis","volume":"39","author":"Treglia","year":"2012","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"6","key":"10.1016\/j.ejca.2021.01.008_bib41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40257-013-0040-x","article-title":"Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with Merkel cell carcinoma: a systematic review and meta-analysis","volume":"14","author":"Treglia","year":"2013","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2021.01.008_bib42","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14310\/horm.2002.1756","article-title":"Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis","volume":"16","author":"Treglia","year":"2017","journal-title":"Hormones (Athens)"},{"issue":"9","key":"10.1016\/j.ejca.2021.01.008_bib43","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1210\/js.2018-00087","article-title":"Diagnosing nonfunctional pancreatic NETs in MEN1: the evidence base","volume":"2","author":"van Treijen","year":"2018","journal-title":"J Endocr Soc"},{"issue":"4","key":"10.1016\/j.ejca.2021.01.008_bib44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0284185113496679","article-title":"Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis","volume":"55","author":"Yang","year":"2014","journal-title":"Acta Radiol"},{"issue":"3","key":"10.1016\/j.ejca.2021.01.008_bib45","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2967\/jnumed.118.211706","article-title":"Performance of 68Ga-DOTA\u2013Conjugated somatostatin receptor\u2013targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis","volume":"60","author":"Han","year":"2019","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.ejca.2021.01.008_bib46","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1210\/jc.2009-2604","article-title":"123I-Meta-Iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis","volume":"95","author":"Jacobson","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2B","key":"10.1016\/j.ejca.2021.01.008_bib47","first-page":"1599","article-title":"Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas--experience and meta-analysis","volume":"26","author":"Van Der Horst-Schrivers","year":"2006","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2021.01.008_bib48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12020-015-0544-7","article-title":"The incremental benefit of functional imaging in pheochromocytoma\/paraganglioma: a systematic review","volume":"50","author":"Brito","year":"2015","journal-title":"Endocrine"},{"issue":"12","key":"10.1016\/j.ejca.2021.01.008_bib49","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0284185118764206","article-title":"68Ga-somatostatin receptor analogs and 18F-FDG PET\/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis","volume":"59","author":"Kan","year":"2018","journal-title":"Acta Radiol"},{"issue":"5","key":"10.1016\/j.ejca.2021.01.008_bib50","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.ejca.2021.01.008_bib51","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.ejca.2021.01.008_bib52","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.clon.2011.12.003","article-title":"Radionuclide therapy in neuroendocrine tumours: a systematic review","volume":"24","author":"Gulenchyn","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ejca.2021.01.008_bib53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/snuc.2002.31022","article-title":"Somatostatin receptor imaging","volume":"32","author":"Kwekkeboom","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.ejca.2021.01.008_bib54","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1007\/s00259-011-1833-x","article-title":"Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y\/177Lu-DOTATATE: which is a better therapy option?","volume":"38","author":"Kunikowska","year":"2011","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"4","key":"10.1016\/j.ejca.2021.01.008_bib55","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s00259-020-04690-5","article-title":"Tandem peptide receptor radionuclide therapy using 90Y\/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience","volume":"47","author":"Kunikowska","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"10","key":"10.1016\/j.ejca.2021.01.008_bib56","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1200\/JCO.2011.37.2151","article-title":"Cohort study of somatostatin-based radiopeptide therapy with [90 Y-DOTA]-TOC versus [90 Y-DOTA]-TOC plus [177 Lu-DOTA]-TOC in neuroendocrine cancers","volume":"30","author":"Villard","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.01.008_bib57","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s00259-017-3821-2","article-title":"Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis","volume":"45","author":"Thang","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"6","key":"10.1016\/j.ejca.2021.01.008_bib58","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00259-017-3925-8","article-title":"Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index","volume":"45","author":"Nicolini","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"4_suppl","key":"10.1016\/j.ejca.2021.01.008_bib59","first-page":"604","article-title":"First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +\/\u2212 capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs)","volume":"38","author":"Pavlakis","year":"2020","journal-title":"J Clin Orthod"},{"issue":"11","key":"10.1016\/j.ejca.2021.01.008_bib60","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2967\/jnumed.115.158899","article-title":"Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0,Tyr3]octreotate","volume":"56","author":"van Vliet","year":"2015","journal-title":"J Nucl Med"},{"issue":"16","key":"10.1016\/j.ejca.2021.01.008_bib61","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-Term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Canc Res"},{"issue":"6","key":"10.1016\/j.ejca.2021.01.008_bib62","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2021.01.008_bib63","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.01.008_bib64","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.01.008_bib65","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.7150\/thno.18068","article-title":"Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance","volume":"7","author":"Chan","year":"2017","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.ejca.2021.01.008_bib66","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/cncr.23469","article-title":"Functional imaging of neuroendocrine tumors with combined PET\/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG","volume":"112","author":"Kayani","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2021.01.008_bib67","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00259-014-2906-4","article-title":"Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours","volume":"42","author":"Kashyap","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"6","key":"10.1016\/j.ejca.2021.01.008_bib68","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00259-013-2369-z","article-title":"Role of 18FDG PET\/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours","volume":"40","author":"Severi","year":"2013","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.ejca.2021.01.008_bib69","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-016-3533-z","article-title":"Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE","volume":"44","author":"Sansovini","year":"2017","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.ejca.2021.01.008_bib70","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","article-title":"18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors","volume":"16","author":"Binderup","year":"2010","journal-title":"Clin Canc Res"},{"issue":"3","key":"10.1016\/j.ejca.2021.01.008_bib71","first-page":"240","article-title":"Effect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes - [90Y]Y\/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on qualification [18F]FDG PET\/CT in Polish multicenter experience - do we need [18F]FDG","volume":"71","author":"Zemczak","year":"2020","journal-title":"Endokrynol Pol"},{"key":"10.1016\/j.ejca.2021.01.008_bib72","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00259-014-2892-6","article-title":"(68)Ga-DOTATOC PET\/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT\/CT","volume":"42","author":"Kroiss","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ejca.2021.01.008_bib73","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT","volume":"48","author":"Gabriel","year":"2007","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.ejca.2021.01.008_bib74","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ejca.2021.01.008_bib75","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Canc"},{"issue":"9","key":"10.1016\/j.ejca.2021.01.008_bib76","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/S1470-2045(15)00186-2","article-title":"Consensus on biomarkers for neuroendocrine tumour disease","volume":"16","author":"Oberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.01.008_bib77","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1530\/EC-16-0043","article-title":"A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management","volume":"5","author":"Oberg","year":"2016","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.ejca.2021.01.008_bib78","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ejca.2021.01.008_bib79","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","article-title":"Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning","volume":"45","author":"Cremonesi","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.ejca.2021.01.008_bib80","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2967\/jnumed.112.107524","article-title":"Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment","volume":"54","author":"Sandstrom","year":"2013","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.ejca.2021.01.008_bib81","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00259-015-3001-1","article-title":"Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment","volume":"42","author":"Svensson","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2","key":"10.1016\/j.ejca.2021.01.008_bib82","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.114.148437","article-title":"Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"56","author":"Ilan","year":"2015","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.ejca.2021.01.008_bib83","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","author":"Garske-Rom\u00e1n","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.ejca.2021.01.008_bib84","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40658-018-0210-2","article-title":"Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy","volume":"5","author":"Sundl\u00f6v","year":"2018","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.ejca.2021.01.008_bib85","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.119.240366","article-title":"OpenDose: open access resources for nuclear medicine dosimetry","author":"Chauvin","year":"2020","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.ejca.2021.01.008_bib86","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.humpath.2014.11.012","article-title":"Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas","volume":"46","author":"Elston","year":"2015","journal-title":"Hum Pathol"},{"issue":"52","key":"10.1016\/j.ejca.2021.01.008_bib87","doi-asserted-by":"crossref","first-page":"89958","DOI":"10.18632\/oncotarget.21194","article-title":"Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas","volume":"8","author":"Kaemmerer","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.ejca.2021.01.008_bib88","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2021.01.008_bib89","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2021.01.008_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8070952","article-title":"A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation","volume":"8","author":"Kolasinska-\u0106wik\u0142a","year":"2019","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.ejca.2021.01.008_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070909","article-title":"Favorable outcome in patients with pheochromocytoma and paraganglioma treated with 177Lu-DOTATATE","volume":"11","author":"Vyakaranam","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejca.2021.01.008_bib92","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"181","author":"Zandee","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ejca.2021.01.008_bib93","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2967\/jnumed.117.199760","article-title":"Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study","volume":"59","author":"Nicolas","year":"2018","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.ejca.2021.01.008_bib94","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2967\/jnumed.117.199737","article-title":"Safety, biodistribution, and radiation dosimetry of 68Ga-OPS202 in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase I imaging study","volume":"59","author":"Nicolas","year":"2018","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.ejca.2021.01.008_bib95","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.2967\/jnumed.111.095778","article-title":"Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in\u00a0vitro","volume":"52","author":"Cescato","year":"2011","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"10.1016\/j.ejca.2021.01.008_bib96","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","article-title":"Somatostatin receptor antagonists for imaging and therapy","volume":"58","author":"Fani","year":"2017","journal-title":"J Nucl Med"},{"issue":"13","key":"10.1016\/j.ejca.2021.01.008_bib97","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1007\/s00259-018-4101-5","article-title":"Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET\/CT, SPECT\/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study","volume":"45","author":"Antwi","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"7","key":"10.1016\/j.ejca.2021.01.008_bib98","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2967\/jnumed.110.085142","article-title":"Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas","volume":"52","author":"Wild","year":"2011","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.ejca.2021.01.008_bib99","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/MNM.0000000000000008","article-title":"Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging","volume":"34","author":"Chondrogiannis","year":"2013","journal-title":"Nucl Med Commun"},{"issue":"4","key":"10.1016\/j.ejca.2021.01.008_bib100","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00259-019-04601-3","article-title":"PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest","volume":"47","author":"Bodei","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"7","key":"10.1016\/j.ejca.2021.01.008_bib101","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00259-018-3967-6","article-title":"PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy","volume":"45","author":"Bodei","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ejca.2021.01.008_bib102","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1053\/j.semnuclmed.2019.11.003","article-title":"Targeted \u03b1-emitter therapy of neuroendocrine tumors","volume":"50","author":"Kunikowska","year":"2020","journal-title":"Semin Nucl Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921000198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921000198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:30:02Z","timestamp":1760733002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921000198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":102,"alternative-id":["S0959804921000198"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus on molecular imaging and theranostics in neuroendocrine neoplasms","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}